Using artificial intelligence (AI) to push development of imaging biomarkers shows great promise to improve disease understanding. This alliance could be a game changer in healthcare, but clinical validation and variability of results must be factored in to advance research, prominent Spanish radiologist explained recently. In clinical practice efforts are already ongoing to apply AI to obtain…
The team of the Heinz Nixdorf Chair of Biomedical Electronics at the Technical University of Munich focuses on innovative diagnostic tools to accelerate the development towards personalized medicine. Therapies tailored to the individual patient – this is the future not only of oncology but of many medical disciplines. “At this point, however,” concedes Professor Dr Oliver Hayden,…
The use of troponin assays to rule in or rule out myocardial infarction (MI) rapidly is critical on several levels. The quick result can reassure the patient that they have not had a heart attack and can return home safely; or, in the event of MI, the relevant treatment can start very soon. It also ensures that clinicians can make the right decision with confidence. Troponin levels have been the…
Advancing technology is allowing scientists increasingly to search for tiny signs of cancer and other health issues in samples of patients’ blood and urine. These “liquid biopsies” are less invasive than a traditional biopsy, and can provide information about what’s happening throughout the body instead of just at a single site. Now researchers at the University of Michigan Rogel Cancer…
Cognitive impairment associated with cancer, also known as “chemobrain”, has gained recognition as a complication of the disease and its treatment, as it can negatively affect the daily lives of cancer patients and survivors. Chemobrain can be subtle yet persistent, with some cancer patients reporting difficulties related to memory and attention even months after completing their treatment.…
A major milestone on its strategic mission to lead in sepsis diagnostics, Beckman Coulter announced that its Early Sepsis Indicator has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Sepsis is a global healthcare crisis that affects more than 30 million people worldwide. The Early Sepsis Indicator is a first-of-its-kind, hematology-based cellular biomarker that is…
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.
Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone. Along with increased deaths, spending on drugs to treat CVD as well as related hospital stays, home health care and lost productivity will also…
Flow cytometry has proved an invaluable diagnostic tool for leukaemia and lymphoma for almost three decades. Now, however, this is evolving in applications to seek out residual disease in cases and in fusion with molecular testing to advance its diagnostic potential. However, although recognised as fast, flexible and accurate, flow cytometry suffers from a lack of standardisation, according to…
It is non-invasive, delivers a chance of early diagnosis, prognostic information and sequential monitoring, and, believes Professor Francesco Salvatore, the enormous potential of liquid biopsies has still to be reached. However, the positive results obtained so far have ‘opened the door to a promising new multi-faceted group of tumour markers, at present collectively designated “liquid…
A commonly used biomarker of kidney disease may also indicate lung problems, particularly COPD, or chronic obstructive pulmonary disease, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Albuminuria, Lung Function Decline, and Risk of Incident COPD: the NHLBI Pooled Cohorts Study,” Elizabeth C.…
Researchers at Cleveland Clinic, University of Oxford, and University of Erlangen have identified a novel imaging biomarker – and found it can be used to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.
A range of new biomarkers and diagnostics for precision cardiovascular medicine were outlined in a session at the British Cardiovascular Society annual conference held recently in Manchester. Speakers from King’s British Heart Foundation Centre looked at how mass spectrometry allows clinicians to measure large numbers of proteins simultaneously, discussed a new biomarker for cardiac ischaemia…
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test. Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a…
ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) congress in Copenhagen, Denmark showed that the test has the potential to avoid a large number of biopsies. “Correlation…
For the first time, scientists at Wake Forest Baptist Medical Center have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid (HA). HA is a naturally occurring molecule that is involved in tissue…
New information on dementia biomarkers is emerging, as increasing results from population studies become available. However, although the list of risk factors lengthens, the value of these predictors, and more generally the cause of disease, remain to be determined, according to Gabriel Krestin, professor and chairman of the Department of Radiology & Nuclear Medicine at Erasmus MC, University…
One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize. For years, prostate-specific antigen (PSA) level, cancer grade and tumor stage have been used to sort prostate cancer patients into risk groups established by the National Comprehensive Cancer Network.…
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. The test is aimed at…
Move over, lab-on-a-chip and lab-on-paper. There’s a new diagnostic technology in research labs that is gaining credibility. It is called lab-on-skin technology and some scientists are quite excited about how it might be used for a variety of clinical purposes. A recent story published in ACS Nano titled, “Lab-on-Skin: A Review of Flexible and Stretchable Electronics for Wearable Health…
A new marker that could be used to diagnose fatal breast cancer up to one year ahead of current methods has been identified in a study led by UCL. The study found that changes detected in a part of DNA which the researches named EFC#93 could suggest early signs of deadly breast cancer. Importantly, these abnormal patterns are present in blood serum before the cancer becomes detectable in the…
Providing insights into new cardiac testing methods, Professor Stefan Holdenrieder, Director of the Institute of Laboratory Medicine at Munich’s German Heart Centre, explained why biomarkers are a game changer in diagnostics.
BBI Solutions (BBI), immunoassay developer and reagent supplier, acquired Maine Biotechnology Services Inc. (MBS) in July 2017, adding antibody development to the firm’s end to end assay development services. This also strengthens BBI’s reagents antibodies portfolio, providing a wide range of high quality biomarkers for infectious disease.
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer’s disease (AD). The discovery, published in Nature Communications, may also provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson’s disease, as well as glioblastoma, brain injuries and stroke. “Our goal was to…
21st century challenges are multitudinous for all. Ageing populations, a changing disease burden; increasing obesity with associated morbidities – Type 2 diabetes, cancer and cardiovascular disease; climate change pressures and more. Any new build plan demands a low carbon footprint; respect for the environment is paramount. To capture all those elements, the plan to regenerate a previously 10…